How Big is the Point-of-Care Diagnostics Market? $18 Billion and Climbing

Our new report finds lots of activity and opportunity in near patient testing. The POC diagnostic industry is part of a paradigm shift from curative medicine to predictive, personalized and preemptive medicine as emerging technological innovations in smartphones, biosensors, lab-on-a-chip and wearable devices are transforming the POC landscape. New technologies are making the concept more viable than ever.


7 Things to Know About Urgent Care Centers

7 Things to Know About Urgent Care Centers

A sleeper health trend, urgent care centers have been around since the 1970's. But now they are getting attention. They offer walk-in care, great hours, and a wide-range of services. From location growth to booming business, here's seven things to know about urgent care centers from Kalorama's newly-published report on these facilities.


Envisioning an Essential Diagnostics List (EDL) and Its IVD Market Impact

Envisioning an Essential Diagnostics List (EDL) and Its IVD Market Impact

Kalorama Information offers relevant market research in the areas of molecular point-of-care (POC) diagnostics , traditional POC diagnostics , and physician office laboratory (POL) test markets. Market information in this post was drawn from the associated reports.

In a recent article of the New England Journal of Medicine (NEJM), health and medical experts convincingly argued for the establishment of an Essential Diagnostics List (EDL) modeled on the existing Essential Medicines List (EML). T...


New Developments in Point-of-Care (POC) Diagnostics - Kalorama White Paper

New Developments in Point-of-Care (POC) Diagnostics - Kalorama White Paper

This post was adapted from a recently released Kalorama Information white paper on clinical point-of-care diagnostics. To receive the white paper, contact a customer service representative at 1-800-298-5603 (intl. +1 240 747 3096) or customerservice@kaloramainformation.com to register your company for free at www.kaloramainformation.com. For additional current and authoritative analysis of the POC diagnostics market, consult Kalorama Information’s market research report The World Market for Poin...


Large Market for Point of Care Testing

Large Market for Point of Care Testing

The market for point of care diagnostics reached $17 billion, in 2014, according to our most recent report on the topic. Expect solid competitive activity, but tempered growth due to pricing strategies that continue to discount the cost of point of care (or POC) diagnostic testing in some segments and higher cost in other segments of testing.

For information on the report, see http://www.kaloramainformation.com/Point-Care-POC-9030928/


The menu for point-of-care testing continues to expand. ...


Recapping the ’Doc Fix’ Act’s Impacts on Medicare Lab Reimbursement

Recapping the ’Doc Fix’ Act’s Impacts on Medicare Lab Reimbursement

The clinical lab and IVD industries continue to assess the “Doc Fix” Bill or Protecting Access to Medicare Act of 2014 (H.R. 4032) following its passage in April 2014. The law, to be implemented by 2017, has seen no shortage of reactions from stakeholders. Under its provisions, the Act will allow CMS to systematically collect test payment rate and volume data from “applicable” private labs, including at least reference or commercial labs and likely hospital labs (or those with outreach businesse...


With Home HbA1c Testing, Industry Won’t Give Up the Ghost

With Home HbA1c Testing, Industry Won’t Give Up the Ghost

Glycated hemoglobin (HbA1c or simply A1c) is one the greatest clinical and IVD industry success stories of the past decade, but has faltered on one front - home testing or patient self-testing. A seemingly natural extension of self-monitoring of blood glucose (SMBG), the market for CLIA-waived home use HbA1c tests has struggled through significant field testing error (and lot-to-lot variation in studies), limited reimbursement coverage, and a lack of resonance with patients and clinicians. Yet, ...


On the Prospect of CLIA-Waived Differentials

On the Prospect of CLIA-Waived Differentials

Hematology testing such as complete blood counts (CBC) and differentials is customarily the domain of clinical laboratories. Instrument automation and the innovation of compact, streamlined models, however, has made such testing possible outside of the lab. Today’s hematology analyzers range from autoloaded, high-throughput and flow cytometry-capable in the lab to closed-menu, benchtop and ease-of-use at a clinic or physician’s office. While labs in the developing world continue to fuel market g...